Advance T cell therapy research into the clinic with a novel lipid nanoparticle (LNP) platform. This platform enables cell therapy researchers to establish a clinically-relevant method for ex vivo gene delivery and editing Genetically modifying immune cells against tumors is a promising anti-cancer therapy. However, current gene delivery methods have significant challenges, hindering further innovations in cell therapies. Non-viral electroporation method can be harsh on cells, making it difficult to generate quality cells at high yields, whereas conventional viral vector delivery method is expensive and cumbersome to manufacture. GenVoy-ILM™️ T Cell Kit for mRNA, a first-to-market lipid nanoparticle reagent kit, overcomes these limitations to enable RNA delivery into human primary T cells with high efficiency while maintaining high cell viability. This kit can be easily tuned and scaled across the NanoAssemblr®️ NxGen microfluidic platform from discovery to the clinic.
